This first-line protocol addresses acromegaly in patients presenting with only modest serum IGF-1 elevation and mild signs and symptoms of growth hormone excess — a specific clinical sub-population where the presentation is less pronounced but active management is indicated.
Modest elevation of serum IGF-1 with mild signs and symptoms of growth hormone excess. This scenario calls for a structured, evidence-based approach to confirm the diagnosis and initiate primary treatment.
The recommended first-line intervention is transsphenoidal surgery — the complete technique details, procedural specifics, and post-operative monitoring pathway are set out in the full protocol.
Success is defined by normalization of serum IGF-1 and biochemical control of GH levels, assessed at 12 weeks after the intervention. Specific remission thresholds and how to interpret results are detailed in the protocol.
DOI: 10.1210/jc.2014-2700
In a patient with only modest elevations of serum IGF-1 and mild signs and symptoms of GH excess, we suggest a trial of a dopamine agonist, usually cabergoline, as the initial adjuvant medical therapy.
We recommend transsphenoidal surgery as the primary therapy in most patients.
A serum GH < 0.14 µg/L suggests "surgical remission," and a level < 1 µg/L indicates "control" and normalization of the mortality risk.
IGF-1 levels measured at 12 weeks after surgery are a valid reflection of surgical remission.
View source ↗